Cost-effectiveness of propofol anesthesia using target-controlled infusion compared with a standard regimen using desflurane

The cost-effectiveness of propofol anesthesia using target-controlled infusion (TCl) versus a standard regimen using desflurane for anesthesia maintenance was analyzed This observational study consisted of 100 inpatients 18 to 75 years old with an American Society of Anesthesiologists physical status of I or 11 who were scheduled for otological surgery lasting less than four hours. Patients received one of two treatments. The desflurane-maintenance group received propofol 2-4 mg/kg and sufentanil 0.15-0.30 mug (as the citrate)/kg. A, constant fresh gas flow of 1 L/min was used during maintenance of anesthesia. The propofol-maintenance group received,TCl propofol and an additional infusion of sufentanil. Anesthesia was induced with 0.15-0.30 mug/kg. One blinded evaluator assessed the postoperative recovery from anesthesia for all patients. The cost of drugs and medical devices used during the intra-operative and postoperative periods was calculated. Effectiveness was defined as the absence of postoperative nausea and vomiting (PONV), while the cost-effectiveness of each procedure was the cost per PONV-free episode. The efficiency of each procedure represented the production of effectiveness per dollar invested. Chi-square and t tests, sensitivity analysis, and logistic regression were also performed. The only intergroup difference detected was the frequency of PONV occurring in the early recovery phase (11 in the desflurane group versus 2 in the propofol group). Of those patients requiring antiemetic rescue, 9 were in the desflurane group and only 2 were in the propofol group (p < 0.05). The TO propofol regimen was more expensive than the desflurane regimen ($45 versus $28 per patient, respectively) (p < 0.001). The differential cost-effectiveness ratio was $94.7 per PONV-free episode. PONV 24 hours after surgery and patient satisfaction were similar between groups. A standard regimen of desflurane was more cost-effective than TO propofol for anesthesia maintenance in achieving PONV-free episodes.